Taken together, these data illustrate the potency of the PI3K/mTOR inhibitor NVP-BEZ235 against two different MYCN-driven tumor models, establish that the mechanism of action relates to elimination of MYCN protein, and highlight the potential for treatment of MYCN-driven malignancies in children using clinically available inhibitors of mTOR. This evidence concerns the gene MYCN and neoplasm.